More on ATNM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.00 |
|
|||
| Open | $1.00 | ||||
| 52 Wk High | $3.50 | ||||
| 52 Wk Low | $0.86 | ||||
| Day High | $1.00 | ||||
| Day Low | $1.00 | ||||
| P/E | N/A | ||||
| EPS | $-7.61 | ||||
| Volume | 2,337 | ||||
- Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
- Form 8-K Actinium Pharmaceuticals For: Aug 12
- Form 10-Q Actinium Pharmaceuticals For: Jun 30
- Form 8-K Actinium Pharmaceuticals For: Jun 18
- Actinium presents ATNM-400 data at SNMMI showing activity in lung cancer
- Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
- Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
- Actinium Pharmaceuticals names Steffen Heeger as chief medical officer
- Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
- Actinium Pharmaceuticals presents CAR optimization data at SNMMI 2026
Entities mentioned with ATNM
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S3 | View Related Stories »
- Show More...
